CD7 and neoplasm: CD7 and TCR alpha chain-deficient CD7 CAR-T cells (UCART7) manufactured by CRISPR/Cas9 gene editing technology were used in the CD7+ T-ALL cell lines MOLT-3 (ACC 84), MOLT-4 (ACC 362), HSB-2 (ACC 435) and CCRF-CEM (ACC 240), the CCRF-CEM xenograft models and patient-derived xenograft models all showed better anti-tumor effects and significantly reduced fratricide [57].